001447897 000__ 03099cam\a2200433Ia\4500
001447897 001__ 1447897
001447897 003__ OCoLC
001447897 005__ 20230310004141.0
001447897 006__ m\\\\\o\\d\\\\\\\\
001447897 007__ cr\un\nnnunnun
001447897 008__ 220703s2022\\\\sz\\\\\\ob\\\\001\0\eng\d
001447897 020__ $$a9783030946586$$q(electronic bk.)
001447897 020__ $$a3030946584$$q(electronic bk.)
001447897 020__ $$z3030946576
001447897 020__ $$z9783030946579
001447897 0247_ $$a10.1007/978-3-030-94658-6$$2doi
001447897 035__ $$aSP(OCoLC)1334101856
001447897 040__ $$aYDX$$beng$$cYDX$$dGW5XE$$dEBLCP$$dSFB$$dOCLCF$$dOCLCQ
001447897 049__ $$aISEA
001447897 050_4 $$aRC271.R3
001447897 08204 $$a616.99/40642$$223/eng/20220708
001447897 1001_ $$aSchultheiss, Timothy E.,$$d1951-
001447897 24510 $$aRadiation myelopathy /$$cTimothy Schultheiss.
001447897 260__ $$aCham, Switzerland :$$bSpringer,$$c2022.
001447897 300__ $$a1 online resource
001447897 504__ $$aIncludes bibliographical references and index.
001447897 5050_ $$aHistory -- Pathogenesis of radiation myelopathy -- Clinical radiation myelopathy -- Radiation myelopathy in stereotactic radiosurgery -- Experimental studies on fractionation effects -- Experimental studies on volume effects -- Other clinical and experimental studies -- Multispecies dose response model -- Treatment of myelopathy -- Medico-legal issues.
001447897 506__ $$aAccess limited to authorized users.
001447897 520__ $$aThis book covers every aspect of radiation myelopathy and considers the evidence from all species in which it has been studied. The historical and current understanding of the pathogenesis of this rare but devastating injury is first discussed. The evidence regarding the role of a variety of factors in radiation myelopathy is then reviewed. Readers will find detailed information on the impacts of total radiation dose, radiation volume, dose fractionation, hyper fractionation, age, anatomic level, comorbidities, radiation modifiers, other therapies, and retreatment of the spinal cord. Given the similarity of the pathogenesis of radiation myelopathy in humans and experimental animals, the potential for cross-species modelling of dose response is explored, with attention to relevant species differences. Treatment of the condition is also fully considered. New theories are presented regarding retreatment, small volume response, and the final step in white matter necrosis. The final chapter addresses the medicolegal issues elicited by radiation myelopathy, which is often the result of treatment error. Radiation Myelopathy will be of high value for radiation oncologists, radiation physicists, dosimetrists, biologists, neurologists, medical oncologists, and attorneys.
001447897 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed July 8, 2022).
001447897 650_0 $$aCancer$$xRadiotherapy$$xComplications.
001447897 655_0 $$aElectronic books.
001447897 77608 $$iPrint version: $$z3030946576$$z9783030946579$$w(OCoLC)1288663322
001447897 852__ $$bebk
001447897 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-94658-6$$zOnline Access$$91397441.1
001447897 909CO $$ooai:library.usi.edu:1447897$$pGLOBAL_SET
001447897 980__ $$aBIB
001447897 980__ $$aEBOOK
001447897 982__ $$aEbook
001447897 983__ $$aOnline
001447897 994__ $$a92$$bISE